Silence Therapeutics plc
SLNDrugs in Pipeline
3
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
2 upcoming, 2 past
Stock Offering — $175M
Silence Therapeutics completed an upsized equity offering of $175 million in American Depositary Shares at $13.50 per share.
1 more catalyst beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How SLN's past catalysts played out
SLN124
Polycythemia Vera
SLN360
Cardiovascular Diseases
Atu027 & gemcitabine in lead in safety period
Carcinoma, Pancreatic Ductal
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
SLN124 | Phase 2 | Polycythemia Vera | - | - |
SLN360 | Phase 2 | Cardiovascular Diseases | - | - |
Atu027 & gemcitabine in lead in safety period | Phase 2 | Carcinoma, Pancreatic Ductal | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Silence Therapeutics plc's drug pipeline?→
CatalystAlert tracks 3 drug candidates in Silence Therapeutics plc's (SLN) pipeline across Phase 2. Its lead program is SLN124 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Silence Therapeutics plc's next FDA catalyst?→
Silence Therapeutics plc's (SLN) next tracked catalyst is a Earnings expected August 6, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track SLN biotech catalysts?→
Add SLN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Silence Therapeutics plc's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.